These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 10071981

  • 1. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ, Finlay GJ, Baguley BC.
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ, Riou JF, Baguley BC.
    Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and its analogues.
    Pastwa E, Ciesielska E, Piestrzeniewicz MK, Denny WA, Gniazdowski M, Szmigiero L.
    Biochem Pharmacol; 1998 Aug 01; 56(3):351-9. PubMed ID: 9744573
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
    Padget K, Stewart A, Charlton P, Tilby MJ, Austin CA.
    Biochem Pharmacol; 2000 Sep 15; 60(6):817-21. PubMed ID: 10930536
    [Abstract] [Full Text] [Related]

  • 7. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Haldane A, Finlay GJ, Hay MP, Denny WA, Baguley BC.
    Anticancer Drug Des; 1999 Jun 15; 14(3):275-80. PubMed ID: 10500502
    [Abstract] [Full Text] [Related]

  • 8. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
    Spicer JA, Finlay GJ, Baguley BC, Velea L, Graves DE, Denny WA.
    Anticancer Drug Des; 1999 Feb 15; 14(1):37-45. PubMed ID: 10363026
    [Abstract] [Full Text] [Related]

  • 9. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.
    Biochem Pharmacol; 2014 Aug 01; 90(3):320-30. PubMed ID: 24915421
    [Abstract] [Full Text] [Related]

  • 10. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
    Spicer JA, Gamage SA, Atwell GJ, Finlay GJ, Baguley BC, Denny WA.
    J Med Chem; 1997 Jun 06; 40(12):1919-29. PubMed ID: 9191970
    [Abstract] [Full Text] [Related]

  • 11. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A, Finlay GJ, Baguley BC.
    Oncol Res; 1993 Jun 06; 5(3):133-8. PubMed ID: 8260750
    [Abstract] [Full Text] [Related]

  • 12. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA, Spicer JA, Atwell GJ, Finlay GJ, Baguley BC, Denny WA.
    J Med Chem; 1999 Jul 01; 42(13):2383-93. PubMed ID: 10395479
    [Abstract] [Full Text] [Related]

  • 13. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH.
    Cancer Res; 1990 Jun 01; 50(11):3311-6. PubMed ID: 2159380
    [Abstract] [Full Text] [Related]

  • 14. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
    Osman S, Rowlinson-Busza G, Luthra SK, Aboagye EO, Brown GD, Brady F, Myers R, Gamage SA, Denny WA, Baguley BC, Price PM.
    Cancer Res; 2001 Apr 01; 61(7):2935-44. PubMed ID: 11306471
    [Abstract] [Full Text] [Related]

  • 15. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
    Hicks KO, Pruijn FB, Baguley BC, Wilson WR.
    J Pharmacol Exp Ther; 2001 Jun 01; 297(3):1088-98. PubMed ID: 11356933
    [Abstract] [Full Text] [Related]

  • 16. Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.
    Wakelin LP, Adams A, Denny WA.
    J Med Chem; 2002 Feb 14; 45(4):894-901. PubMed ID: 11831901
    [Abstract] [Full Text] [Related]

  • 17. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
    Schneider E, Darkin SJ, Lawson PA, Ching LM, Ralph RK, Baguley BC.
    Eur J Cancer Clin Oncol; 1988 Nov 14; 24(11):1783-90. PubMed ID: 2850193
    [Abstract] [Full Text] [Related]

  • 18. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B, Fosse P, Khelifa T, Jacquemin-Sablon A, Bailly C.
    Mol Pharmacol; 1996 Feb 14; 49(2):343-50. PubMed ID: 8632768
    [Abstract] [Full Text] [Related]

  • 19. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
    Woynarowski JM, McCarthy K, Reynolds B, Beerman TA, Denny WA.
    Anticancer Drug Des; 1994 Feb 14; 9(1):9-24. PubMed ID: 8141968
    [Abstract] [Full Text] [Related]

  • 20. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B, Riou JF, Lavelle F, Pommier Y.
    Mol Pharmacol; 1993 Oct 14; 44(4):767-74. PubMed ID: 8232227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.